Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

European Journal of Cancer

Volumn 50, Issue 1, 2014, Pages 78-84

  Bianchini, D ^a   Lorente, D ^a   Rodriguez Vida, A ^b   Omlin, A ^a   Pezaro, C ^a   Ferraldeschi, R ^a   Zivi, A ^a   Attard, G ^a   Chowdhury, S ^b   De Bono, J S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Abiraterone; Androgen receptor targeting; Castration resistant prostate cancer; Enzalutamide; Hormone therapy

Indexed keywords

ABIRATERONE; CABAZITAXEL; DEXAMETHASONE; DOCETAXEL; ENZALUTAMIDE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; METASTASIS; MIDDLE AGED; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE; VERY ELDERLY;

ABIRATERONE; ANDROGEN RECEPTOR TARGETING; CASTRATION RESISTANT PROSTATE CANCER; ENZALUTAMIDE; HORMONE THERAPY;

AGED; AGED, 80 AND OVER; ANDROSTENOLS; HUMANS; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84891633214     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.08.020     Document Type: Article

References (14)

1. J.S. De Bono, C.J. Logothetis, and A. Molina et al. Abiraterone and increased survival in metastatic prostate cancer N Eng J Med 364 21 2011 1995 2005
2. H.I. Scher, K. Fizazi, and F. Saad et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Eng J Med 367 13 2012 1187 1197
3. Y. Loriot, D. Bianchini, and E. Ileana et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol 24 7 2013 1807 1812
4. K.L. Noonan, S. North, and R.L. Bitting et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide Ann Oncol 24 7 2013 1802 1807
5. R. Ferraldeschi, N. Sharifi, R.J. Auchus, and G. Attard Molecular pathways: inhibiting steroid biosynthesis in prostate cancer Clin Cancer Res 19 13 2013 3353 3359
6. H.I. Scher, S. Halabi, and I. Tannock et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 7 2008 1148 1159
7. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247
8. M. McCaffery, and A. Beebe Pain: clinical manual for nursing practice 1993 V.V. Mosby Company Baltimore
9. D.E. Rathkopf, E.S. Antonarakis, and N.D. Shore et al. ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC) ASCO Meet Abstr 31 6 Suppl. 2013 48
10. X.Y. Zhao, P.J. Malloy, and A.V. Krishnan et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat Med 6 6 2000 703 706
11. Y. Li, S.C. Chan, L.J. Brand, and T.H. Hwang et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines Cancer Res 73 2 2013 483 489
12. B. Sahu, M. Laakso, and P. Pihlajamaa et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells Cancer Res 73 5 2013 1570 1580
13. J. Richards, A.C. Lim, and C.W. Hay et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100 Cancer Res 72 9 2012 2176 2182
14. B.S. Carver, C. Chapinski, J. Wongvipat, and H. Hieronymus et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 5 2011 575 586